TILT Biotherapeutics Ltd Email Format
Biotechnology ResearchSouthwest Finland, Finland11-50 Employees
TILT Biotherapeutics Ltd is a clinical-stage biotechnology company developing cancer immunotherapies that combine oncolytic virus strategies with cellular and antibody-based approaches. Based in Helsinki, Finland, it was founded in 2013 by Pr. Akseli Hemminki. Its lead candidate is a TNFα/IL2-armed oncolytic adenovirus currently in clinical development. Multiple Phase I trials are underway, reflecting ongoing clinical evaluation. The company targets oncology researchers and biopharmaceutical developers seeking to integrate viro-immunotherapy with cellular therapies and checkpoint inhibitors. In 2022, the company expanded its presence by opening an office in Boston to support U.S. development and collaborations.